C.S. John Kim

Suppression-Replacement <i>KCNQ1</i> Gene Therapy for Type 1 Long QT Syndrome

Steven M. Dotzler, C.S. John Kim, William A.C. Gendron et al. · Circulation · 2021 · 86 citations · Full text

Medicine, Cardiology, Genetics +15

Promise and Potential Peril With Lumacaftor for the Trafficking Defective Type 2 Long-QT Syndrome-Causative Variants, p.G604S, p.N633S, and p.R685P, Using Patient-Specific Re-Engineered Cardiomyocytes

Bailey J. O’Hare, C.S. John Kim, Samantha K. Hamrick et al. · Circulation Genomic and Precision Medicine · 2020 · 38 citations · Full text

Medicine, Molecular Genetics, Pharmacology +17

<i>KCNQ1</i> suppression-replacement gene therapy in transgenic rabbits with type 1 long QT syndrome

Sahej Bains, Lucilla Giammarino, Saranda Nimani et al. · European Heart Journal · 2024 · 25 citations · Full text

Medicine, Cardiology, Genetics +17

Characterization of N-terminal RYR2 variants outside CPVT1 hotspot regions using patient iPSCs reveal pathogenesis and therapeutic potential

Marissa J. Stutzman, C.S. John Kim, David J. Tester et al. · Stem Cell Reports · 2022 · 11 citations · Full text

Medicine, Molecular Genetics, Cardiovascular Genetics +2